Century Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Century Therapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on December 12, 2025. The company is headquartered in Philadelphia, Pennsylvania, and its common stock trades on the Nasdaq Capital Market under the symbol "IPSC."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of updated investor presentation materials rather than a financial results announcement.
Material Changes
On December 12, 2025, the Company updated information reflected in a slide presentation attached as Exhibit 99.1. This updated presentation is intended for use in various meetings with investors. No other material changes to financial status or operations are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond this standard legal disclaimer.
Investor Verification Checklist
- Review Exhibit 99.1 (Investor Presentation dated December 12, 2025) for the specific updated information referenced in this filing.
- Verify the legal status of the presentation as "furnished" rather than "filed" to understand liability limitations.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Check subsequent filings for any formal incorporation of the presentation data into official financial reports.